About: Big pharma

Drug industry reacts to Oxfam’s allegations of tax-dodging

Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  

Health care risks being forgotten in Brexit talks, industry warns

Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.

Pharma boss: Targeting drugs won’t make healthcare systems more sustainable

“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.

Drugs firms call for phased transition of regulation after Brexit

Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.

Fake drugs cost EU billions of euros, its health and its jobs

Counterfeit drugs are not only hazardous to health, they cost people their jobs too, a new EU study has revealed. But Germans in particular are willing to take risks. EURACTIV's partner Der Tagesspiegel reports.

Don’t be fooled by CETA: It’s a wolf in sheep’s clothing

In his State of the Union speech, Jean-Claude Juncker called the Canada-EU trade agreement the most progressive trade agreement the EU has ever negotiated. It actually poses a genuine threat to the health sector, argues Emma Woodford.

EU needs compulsory transparency register to rein in Big Pharma lobbying

Big Pharma is out-gunning its civil society and non-profit rivals in terms of lobbying, access, and influence at the EU institutions, write David Lundy and Rachel Tansey.